Caplin Point Laboratories Ltd Share Price – NSE  / BSE

Pharmaceuticals, Small Cap

The stock has rallied 20.25% over the last five trading sessions. It has gained 28.03% in one month, 41.16% in three months and 32.28% so far in 2026.

Caplin Point Laboratories is a fully integrated pharmaceutical company with a strong presence in Latin America.

The company reported a 19.32% increase in consolidated net profit to Rs 170.11 crore in Q4 FY26, compared with Rs 142.57 crore in Q4 FY25. Revenue from operations rose 19.45% to Rs 600.16 crore from Rs 502.43 crore a year earlier.

For FY26, emerging markets comprising Latin America and Africa contributed 79% of revenue, while the US market accounted for the remaining 21%.

Last month, Caplin Steriles, a subsidiary of the company, received final approval from the US Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Foscarnet Sodium Injection (6000 mg/250 mL Infusion Bag), a generic version of Foscavir Injection.

The antiviral drug is used to treat CMV retinitis in AIDS patients and HSV infections in immunocompromised individuals. According to IQVIA data, the product recorded US sales of around $15 million in the 12 months ended March 2026.

Powered by Capital Market - Live News

Caplin Steriles (CSL), a subsidiary company of Caplin Point Laboratories has been granted final approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Foscarnet Sodium Injection (6000 mg/250 mL Infusion Bag), a generic therapeutic equivalent version of the Reference Listed Drug (RLD) Foscavir Injection from Clinigen Healthcare, (NDA 020068).

Foscarnet Sodium Injection is an antiviral medication used to treat CMV retinitis in AIDS patients and HSV infection in immunocompromised individuals. According to IQVIATM (IMS Health), Foscarnet Sodium Injection, (6000 mg/250 mL Infusion Bag) had US sales of approximately $15 million for the 12-month period ending March 2026.

Caplin Point Laboratories announced that the Board of Directors of the Company at its meeting held on 14 May 2026, inter alia, have recommended the interim dividend of Rs 4 per equity Share (i.e. 200%) , subject to the approval of the shareholders.

Net profit of Caplin Point Laboratories rose 19.32% to Rs 170.11 crore in the quarter ended March 2026 as against Rs 142.57 crore during the previous quarter ended March 2025. Sales rose 19.45% to Rs 600.16 crore in the quarter ended March 2026 as against Rs 502.45 crore during the previous quarter ended March 2025.

For the full year,net profit rose 19.57% to Rs 641.24 crore in the year ended March 2026 as against Rs 536.31 crore during the previous year ended March 2025. Sales rose 12.89% to Rs 2187.19 crore in the year ended March 2026 as against Rs 1937.47 crore during the previous year ended March 2025.

Powered by Capital Market - Live News